ArtemiX Biotech

Artemix Biotech is an early clinical stage spin-off from the University Hospital of Lausanne and the University of Geneva's School of Pharmaceutical Sciences. The company focuses on addressing the clinical challenges associated with chronic kidney disease, a significant health issue affecting millions globally. Artemix Biotech is developing a novel gel-based drug delivery system designed to improve vascular access during hemodialysis, a critical procedure for kidney disease patients. This gel is applied by surgeons around the vessel post-arteriovenous fistula surgery, releasing the active drug over time to inhibit disease progression. Although their products are still under development and not yet available on the market, Artemix Biotech aims to enhance the primary patency success rate and prevent vessel stenosis. The company operates within the healthcare sector, targeting medical professionals and institutions involved in kidney disease treatment. Artemix Biotech's business model likely involves partnerships with healthcare providers and potential licensing agreements once their products reach the market. The company has received initial financial and entrepreneurial support, positioning itself to contribute significantly to the medical field.